Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance News
TOKYO Reuters) - Takeda Pharmaceutical Co Ltd said it now expects an operating profit for the full year, as opposed to its earlier projection for a loss, due to stronger sales and cost savings from its integration with Shire Plc. The company forecast an operating profit of 10 billion yen $91.91 million) for the year ending in March, versus its previous forecast for a loss of 110 billion yen. That compares with an average loss forecast of 75.6 billion yen from 13 analysts polled by Refinitiv. Takeda surprised markets in May last year when it reversed its full-year profit forecast to a loss, citing costs linked to its $59 billion Shire deal. It later revised the forecast to a smaller loss on strong sales of its core drugs. The Shire acquisition, which was completed in January 2019, expanded Takeda's pipeline and diversified its global sales, with half now coming from the United States. The drugmaker, now the 15th largest in the world by revenue, told investors in November it expects to
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic AreasBusiness Wire
- Dietary Supplements Market in Japan is Expected to Reach USD 2,310.30 Million by 2033, Growing at a 6.2% CAGR | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (TSE:4502) Advances with New Product Update and Strategic Alliances for Growth [Yahoo! Finance]Yahoo! Finance
- Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros TherapeuticsBusiness Wire
TAK
Sec Filings
- 12/18/24 - Form 6-K
- 12/13/24 - Form 6-K
- 12/2/24 - Form 6-K
- TAK's page on the SEC website